Success Metrics

Active Trials

0(0%)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Other(3)

Detailed Status

unknown2

Not yet recruiting1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

unknown250%

not_yet_recruiting125%

suspended125%

Recent Activity

0 active trials

Showing 4 of 4

not_yet_recruitingphase_2

A Study of IMM0306 in IgG4-Related Disease

NCT07621939

unknownphase_1

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

NCT05771883

unknownphase_1

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

NCT05805943

suspendedphase_1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131

Clinical Trials (4)

Showing 4 of 4 trials

NCT07621939Phase 2

A Study of IMM0306 in IgG4-Related Disease

Not Yet Recruiting

NCT05771883Phase 1

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Unknown

NCT05805943Phase 1

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Unknown

NCT04746131Phase 1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Suspended

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4